Published in Obesity and Diabetes Week, April 25th, 2005
According to a study from Germany and the United States, "Glucagon-like peptide 1 (GLP-1) was discovered as an incretin (insulinotropic gut) hormone. Biological actions of GLP-1 in healthy and type 2 diabetic subjects include: stimulation of insulin secretion in a glucose-dependent manner; suppression of glucagon, reduction in appetite and food intake, and deceleration of gastric emptying. In animal experiments, in addition, stimulation of beta-cell neogenesis, growth and differentiation in animal and tissue culture experiments,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.